My Heart Doc approached me for another Cholesterol study, I have been on two others in the past. My LDL got down as low as 23, crazy huh. Anyway this one is from Merck. With all of this mRNA push I checked online about this new study. Sure enough the New PCSK9 Inhibitor is taunted with mRNA technology. This will be a big NO for me. I am scheduled next Wednesday for blood work, free, to see if I qualify. I may go ahead and get the blood work done but bow out after that.
Upcoming Phase 3 Clinical Program Will Examine Efficacy of Oral PCSK9 Inhibitor MK-0616 in Patients With Hypercholesterolemia
The phase 3 clinical program, CORALreef, consists of 3 trials and is likely the first of its kind for an oral PCSK9 inhibitor, according to the study authors.
www.pharmacytimes.com
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616 - Merck.com
Program plans to enroll approximately 17,000 participants across three global studies Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the company’s Phase 3 clinical program, CORALreef, for MK-0616, an investigational, oral proprotein...
www.merck.com
mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor - PMC
Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted ...
www.ncbi.nlm.nih.gov